The multi-year collaboration aims to scale molecular data storage infrastructure and unlock breakthrough cost efficiencies by 2030.
PISCATAWAY, N.J. and LOS ANGELES, April 9, 2026 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of CMOS-based DNA synthesis technologies, and Mimulus Corp, the pioneer in Molecular Archive Technology™, today announced a strategic collaboration to industrialize DNA-based data storage, a technology poised to transform how the world preserves data in the age of Artificial Intelligence.

As the AI-driven surge in global data creation accelerates exponentially, existing archival storage systems built on magnetic tape and hard drives are reaching their economic and environmental limits. The strategic partnership between GenScript and Mimulus aims to address this challenge by architecting the world's first molecular archival storage that requires no electricity to preserve data once encoded into DNA and can store massive volumes of information for centuries.
Under the agreement, GenScript will industrialize high‑throughput DNA synthesis at scale, targeting a leap from millions to billions of oligonucleotides synthesized in parallel on a single chip. Building on its highly-validated manufacturing platform, currently capable of synthesizing 8 million oligonucleotides in parallel on a single chip, GenScript will deliver the scale, reproducibility, and validation required to make emerging applications like molecular data storage commercially viable. While the DNA technology landscape remains fragmented across writing, reading, and storage, GenScript brings capabilities across key parts of the DNA data storage value chain, including synthesis, sequencing-related technologies, and platform development. Combined with Mimulus' proprietary Molecular Archive Technology™, this capability enables molecular data storage to transition from laboratory innovation to commercially scalable infrastructure.
"When a new category emerges, the winners are built on infrastructure," said Sherry Shao, Rotating CEO of GenScript Biotech Corporation. "At GenScript, we believe in Scripting Possibilities - turning what was once theoretical into scalable reality. DNA-based data storage will only become a viable real-world infrastructure when synthesis can be delivered at extraordinary throughput, quality, and cost. We are building that industrial foundation to transform molecular storage from being 'scientific promise' into 'global reality'."
Mimulus Glacier Data Storage Card is replacing decaying magnetic infrastructure. By combining GenScript's proven industrial-scale synthesis engine with Mimulus's molecular transcoding architecture, this credit-card-sized device creates a completely off-stack and off-grid physical vault. The collaboration seeks to dramatically accelerate the cost curve of DNA-based storage and unlock economically viable archival systems for global cloud and AI workloads.
"Trying to solve a pressing 21st-century AI data problem with mid-century magnetic tape is a bit like trying to launch a rocket with a steam engine," said Todd R. Nelson, Ph.D., Founder and Chairman of Mimulus Corp. "But this isn't just about building a better storage device; it's about liquidating an operational liability to fuel the AI revolution. By combining our proprietary architecture with GenScript's unparalleled manufacturing scale, we are printing power permits. We are handing hyperscalers the exact megawatts they need to turn on their AI supercomputers today, unlocking a trillion-dollar flywheel that reshapes the economics of the cloud."
About GenScript Biotech Corporation
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop ground breaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com
About Mimulus Corp
Mimulus Corp is a venture-backed biotechnology company architecting the world's first economically sustainable and physically permanent archival infrastructure for the age of AI. By combining the scaling laws of the semiconductor industry with the density of synthetic biology, Mimulus solves the global archival storage crisis and liberates critical grid power for AI compute. Led by a team of serial entrepreneurs with over $7 billion in capital formation experience, Mimulus is making the future molecular. For more information: www.mimulus.co
Media Contacts:
For GenScript: Melis Inceer, Head of Integrated Communications & Content, melis.inceer@genscript.com
For Mimulus Corp: Colette Patnaude, Founder, press@mimulus.co

Photo - https://mma.prnewswire.com/media/2952816/How_Molecular_Data_Storage_Works.jpg
Logo - https://mma.prnewswire.com/media/2952815/GenScript_Mimulus_Partner_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/genscript-and-mimulus-partner-to-industrialize-dna-based-data-storage-for-the-ai-era-302737775.html
Circus SE hat gemeinsam mit der Finexity AG ihre erste asset-basierte Anleihe im siebenstelligen Volumen erfolgreich platziert und zugleich einen strategischen Finanzierungskorridor für weitere Kapitalmarkttransaktionen von bis zu 50 Millionen Euro eröffnet. Die Emission wurde über die digitale Kapitalmarktplattform von Finexity strukturiert und innerhalb weniger Wochen nach dem Start Mitte März vollständig bei Privatanlegern der Finexity Invest GmbH untergebracht. Circus, ein global tätiges KI-Robotik-Unternehmen mit Fokus auf autonome Versorgungssysteme, nutzt die Mittel, um den Rollout seiner KI-basierten Robotik-Infrastruktur voranzutreiben.
Die Anleihe ist über eine eigens gegründete Zweckgesellschaft (SPV) strukturiert und durch autonome KI-Roboter von Circus besichert, die für die Produktion von Mahlzeiten eingesetzt werden. Dieses Modell verbindet industrielle Asset-Finanzierung mit digitaler Kapitalmarkt-Distribution und soll als Blaupause für die weltweite Skalierung weiterer Robotik-Deployments dienen. Nach Unternehmensangaben unterstreicht der zügige Platzierungserfolg die Investorennachfrage nach asset-basierten Strukturen, die auf planbare Cashflows aus operativen Technologien abzielen.
Parallel zur Ersttransaktion haben Circus und die Finexity Group eine mehrstufige Rahmenvereinbarung über Kapitalmarktfinanzierungen mit einem Gesamtvolumen von bis zu 50 Millionen Euro geschlossen. Damit schaffen beide Partner einen skalierbaren Finanzierungsrahmen, der den globalen Ausbau der Robotik-Infrastruktursysteme von Circus sowohl im Verteidigungssektor als auch im zivilen Bereich unterstützen soll. Finexity sieht Circus als Vertreter einer neuen Generation industrieller Technologieunternehmen mit asset-basierten, kalkulierbaren Zahlungsströmen, denen über strukturierte Emissionen ein effizienter Zugang zum Kapitalmarkt eröffnet werden soll.
Für kommende Transaktionen planen Circus und Finexity eine hybride Anleihestruktur, die eine konventionelle mit einer tokenisierten Tranche kombiniert. Ziel ist es, institutionelle Investoren und digitale Kapitalmarktteilnehmer in einer gemeinsamen Struktur zu adressieren und so die Platzierungskraft deutlich zu erhöhen. Während die erste Anleihe ausschließlich über Finexity Invest vertrieben wurde, soll der Vertrieb künftiger Tranchen breiter aufgesetzt werden: Neben dem eigenen Retail-Zugang sollen auch an den Finexity-Handelsplatz angebundene Vertriebspartner wie Sparkassen und Vermögensverwalter eingebunden werden.